Peter M Kash Net Worth & Insider Trades

Peter M Kash - Director, Nile Therapeutics, Inc

As of July 19, 2011

What is Peter M Kash's Net Worth?

The current estimated net worth of Nile Therapeutics, Inc's Director, Peter M Kash, is estimated to be about $1.1M . Peter M Kash owns about 1,761,738 units of Nile Therapeutics, Inc common stock. In the last 3 years at Nile Therapeutics, Inc, Peter M Kash has sold an estimated value of $0 worth.

What is Peter M Kash's Past Insider Trading?

Peter M Kash's largest purchase order was 4,600 units , worth over $5.48K on December 12, 2008. In total, Peter M Kash has made about 8 transactions over 3 years of their time at Nile Therapeutics, Inc. Peter M Kash usually trades in July, with the busiest year in 2009. The most recent transaction was a purchase order of 98,814 units , worth over $0 on July 9, 2009.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Peter M Kash

Date Range: All Time
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...

InsideArbitrage

Our partner InsideArbitrage provides a full suite of tools and analysis that allows you to find opportunities from the hundreds of insiders transactions filed by company insiders each week. The service includes the popular Insider Weekends articles that highlight the top 5 insider purchases and sales each week as well as detailed analysis of one company each week. The service also includes several custom screens such as the Double Dipper that includes a list of companies that are buying back their shares while their insiders are independently buying stock on the open market for their own portfolios.

What is Peter M Kash's' Mailing Address?

  • Mailing address is 787 Seventh Avenue New York NY 10019 NY

Nile Therapeutics, Inc Executive Compensation

Name
Year
Other Earnings Plans or Compensations
Other Earnings Plans or Compensations
Other Earnings Plans or Compensations
Other Compensation
Other Earnings Plans or Compensations
Jonathan DrachmanJonathan Drachman 2020 $4,468,538 $4,468,538 $4,468,538 - $4,468,538
Jonathan DrachmanJonathan Drachman 2019 $3,823,038 $3,823,038 $3,823,038 - $3,823,038
Robert Ho 2020 $2,654,271 $2,654,271 $2,654,271 - $2,654,271
Holly Vance 2020 $2,091,819 $2,091,819 $2,091,819 - $2,091,819
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1404644/000119312521102235/d129921ddef14a.htm

What are Nile Therapeutics, Inc's Past Insider Trades?

Nile Therapeutics, Inc's most recent insider trade came on August 17, 2023 by Baker Bros Advisors Lp, Lp, Baker Brothers Life Sciences Lp, Felix Baker, Julian Baker and Baker Bros Advisors GP Llc who bought 2,285,342 units worth $1.46M . In the last 15 years, insiders at Nile Therapeutics, Inc have sold an estimated value of $739.74K and bought an estimated value of $38.53M worth of shares. Insider trading is most common in May, with the busiest year in 2021. The most active traders at the company are Carl Walkey, Senior Vice President,  Daron Evans, Chief Financial Officer,  and Joshua A Kazam, President & CEO .

Nile Therapeutics, Inc. Insider Trades

Date Range: All Time
Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...